Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations
Investigative Ophthalmology & Visual Science2019Vol. 60(7), pp. 2474–2474
Citations Over TimeTop 11% of 2019 papers
Getachew Boru, Colleen M. Cebulla, Klarke M. Sample, James B. Massengill, Frederick H. Davidorf, Mohamed H. Abdel‐Rahman
Abstract
Our results indicate that there is marked variation in MAPK activation in UM with GNAQ/11 mutations. Thus, GNAQ/11 mutational status is not a sufficient biomarker to adequately predict UM patient responses to single-agent selective MEK inhibitor therapy.
Related Papers
- → GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis(2016)70 cited
- → Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi(2016)70 cited
- → Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas(2017)23 cited
- → Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations(2019)23 cited
- → Progress of GNAQ/GNA11 mutation in uveal melanoma(2018)